Researchers discover unexpected role of an immune system receptor; blocking it halts human cancer cell growth and improves survival in animal models
For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant. This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression.
To wit: The one-year relative survival rate for pancreatic cancer is 20 percent, according to the American Cancer Society. The five-year rate is just 7 percent.
The reason: Current multidrug chemotherapy regimens targeting pancreatic cancer typically do not fully eradicate all cancer cells, leaving behind drug-resistant cells that harbor aberrant stem cell properties and can drive tumor regrowth and metastasis.
In a new paper publishing in the April 4, 2019 online issue of Cell, an international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies —and thus vulnerabilities — of pancreatic cancer stem cells.
Most notably, they found that a key hormone receptor called retinoic acid receptor-related orphan receptor gamma or ROR?, previously studied in inflammation and T-cell differentiation, was especially active during pancreatic cancer progression, and that blocking it markedly slowed patient derived tumor growth and improved survival in animal models.
“These studies revealed an unexpected role for immuno-regulatory genes in the maintenance of the most aggressive, drug-resistant cells in pancreatic cancer,” said senior study author Tannishtha Reya, PhD, UC San Diego professor in the departments of Pharmacology and Medicine. In particular, ROR? emerged as a key regulator. ROR? rose with cancer progression and its inhibition through genetic and pharmacological approaches resulted in a striking defect in pancreatic cancer growth.
“Our work shows that immune system signals are hijacked by pancreatic cancer, and suggests that therapies currently being tested for autoimmune indications should be considered for testing in pancreatic cancer,” said Reya.
Using genome scale approaches to map stem cell dependencies in pancreatic cancer “will be invaluable for understanding the basis of therapy resistance and recurrence and for discovering new vulnerabilities in pancreatic cancer,” said Reya. “Beyond providing new scientific insight, this work can help identify pathways for which clinical grade inhibitors may already exist and can thus be rapidly tested in pancreatic cancer.”
In particular, she said the discovery of ROR?‘s role in promoting tumor growth provides a new avenue for research and potential therapies. “One exciting aspect is the possibility that nuclear hormone receptors could represent therapeutic targets for pancreatic cancer. In fact, drugs targeting ROR? have already been developed by several pharmaceutical companies, and are in trials for autoimmune diseases. Our findings suggest that these agents could also be a valuable therapeutic strategy for pancreatic cancer.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Erytech Pharma: Targeting Pancreatic Cancer, Interesting But Doubtful Investmenton July 4, 2019 at 11:44 am
ERYP has a history of past failures and abandoned programs, and extreme low volume trading in all markets. However, it has also produced promising results in the deadly and untreatable 2nd line ... […]
- Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinomaon July 4, 2019 at 9:58 am
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer featured with high intra-tumoral heterogeneity and poor prognosis. To comprehensively delineate the PDAC ... […]
- Role of keratan sulfate expression in human pancreatic cancer malignancyon July 4, 2019 at 2:23 am
Keratan sulfate (KS) is a sulfated linear polymer of N-acetyllactosamine. Proteoglycans carrying keratan sulfate epitopes were majorly observed in cornea, cartilage and brain; and mainly involved in ... […]
- Findings suggest new ways to help the immune system fight pancreatic canceron July 3, 2019 at 11:49 pm
Findings published today in the journal Science Translational Medicine suggest that a type of white blood cell called tumor associated macrophages (TAMs) that have been deceived by pancreatic cancer ... […]
- Compound puts pancreatic cancer in immunotherapy's sightson July 3, 2019 at 9:38 pm
Scientists have discovered a new way to weaponize the immune system against a historically crafty foe – pancreatic cancer(Credit: vitanovski/Depositphotos) Immunotherapy is a form of cancer ... […]
- Facing pancreatic cancer, Georgia veteran finds hopeon July 3, 2019 at 1:56 pm
ATLANTA (FOX 5 Atlanta) - It's been almost a year since Jerry Keefer found hope in the darkest of places. "Divine intervention is what I call it," Keefer says, looking back on his journey. "Divine," ... […]
- Immune-boosting compound makes immunotherapy effective against pancreatic canceron July 3, 2019 at 11:03 am
Pancreatic cancer is especially challenging to treat—only eight percent of patients are still alive five years after diagnosis. Chemotherapy and radiation therapy are of limited benefit, and ... […]
- Congressman Alcee Hastings, battling pancreatic cancer, says he’ll run for re-election and see Donald Trump’s defeat in 2020on July 2, 2019 at 4:14 am
Congressman Alcee Hastings, who has been under treatment for months for Stage 4 pancreatic cancer, says he’s running for re-election in 2020 — and hoping that on the same day he’ll see President ... […]
- Cancer cell's 'self eating' tactic may be its weaknesson July 1, 2019 at 10:53 pm
Researchers reveal how pancreatic cancer cells adapt to the low energy environment of a tumor: by eating their own mitochondria! Now, by targeting this process, researchers hope to halt cancer cell ... […]
- United States Pancreatic Cancer Market and Competitive Landscape Report 2019 - ResearchAndMarkets.comon July 1, 2019 at 2:00 am
The "US Pancreatic Cancer Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering. United States Pancreatic Cancer Market and Competitive Landscape ... […]
via Bing News